Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $290

Benzinga · 08/03 21:18
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $282 to $290.